Results 311 to 320 of about 26,337,030 (428)

Ubiquitination of transcription factors in cancer: unveiling therapeutic potential

Molecular Oncology, EarlyView.
In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley   +1 more source

Enhanced Environmental Disinfection [PDF]

, 2018
Anderson, Deverick J, MD, MPH, FIDSA, FSHEA
core   +1 more source

Iron concentration in deep gray matter structures is associated with worse visual memory performance in healthy young adults [PDF]

, 2017
Altbäcker, Anna, Bereczkei, Tamás, Clemens, Zsófia, Darnai, Gergely, Horváth, Réka, Janszky, József Vladimír, John, Flora, Komoly, Sámuel, Kovács, Norbert, Nagy, Szilvia Anett, Orsi, Gergely, Perlaki, Gábor, Plózer, Enikő, Schwarcz, Attila, Tényi, Dalma, Varga, Eszter, Weintraut, Rita, Ács, Péter   +17 more
core   +2 more sources

Peripheral Geographic District and Low Socioeconomic Status Are Associated With Decreased Access to Biologics in Patients With Rheumatoid Arthritis. [PDF]

Musculoskeletal Care
Hassan F, Paz Z, Saab A, Cohen AG, Merzon E, Green I, Naffaa ME.   +6 more
europepmc   +1 more source

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

Chronic inflammation in the etiology of disease across the life span

Nature Network Boston, 2019
David Furman, J. Campisi, E. Verdin, Pedro Carrera-Bastos, S. Targ, C. Franceschi, L. Ferrucci, D. Gilroy, A. Fasano, G. Miller, Andrew H. Miller, A. Mantovani, C. Weyand, N. Barzilai, J. Goronzy, T. Rando, R. Effros, A. Lucia, N. Kleinstreuer, George M. Slavich   +19 more
semanticscholar   +1 more source

The case for including proteomics in routine diagnostic practice for rare disease. [PDF]

Genome Med
McCormick EM.
europepmc   +1 more source

Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer

Molecular Oncology, EarlyView.
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen, Chung‐Teng Wang, Jia‐Ming Chang, Ai‐Li Shiau, Gia‐Shing Shieh, Yau‐Lin Tseng, Yi‐Ting Yen, Tang‐Hsiu Huang, Li‐Hsin Cheng, Yu‐Chih Wu, Chao‐Liang Wu, Bing‐Hua Su, Pensee Wu   +12 more
wiley   +1 more source

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Journal of Neurology Neurosurgery & Psychiatry, 1992
A. Hughes, S. Daniel, L. Kilford, A. J. Lees, London Wcln, J. Hughes   +5 more
semanticscholar   +1 more source

Unveiling the potential of artificial intelligence in revolutionizing disease diagnosis and prediction: a comprehensive review of machine learning and deep learning approaches. [PDF]

Eur J Med Res
Sadr H, Nazari M, Khodaverdian Z, Farzan R, Yousefzadeh-Chabok S, Ashoobi MT, Hemmati H, Hendi A, Ashraf A, Pedram MM, Hasannejad-Bibalan M, Yamaghani MR.   +11 more
europepmc   +1 more source